ReNeuron reports more data on ReN003
UK company, ReNeuron, has announced further preclinical data for its stem cell therapy program for diseases of the retina.
The study was performed at the Schepens Eye Research Institute at Harvard Medical School. The ReN003 human retinal progenitor cells were tested in a rodent model of damaged retina. Between 14 and 28 days after transplantation into the sub-retinal space, the cells were seen to integrate with the host retinal tissue, even dividing into the sub-categories of cells found in a healthy retina.
The prototype treatment has the potential to heal retinas damaged by blindness-causing diseases, such as retinitis pigmentosa, age-related macular degeneration and diabetic retinopathy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze